
The study reported efficacy and safety outcomes of the PRESERFLO™ MicroShunt compared with trabeculectomy, the current gold‐standard treatment for advanced glaucoma, in the early and intermediate postoperative period. The study is part of the Dresden Glaucoma and Treatment Study (DGTS), which was not randomised but used a uniform study design, with the same inclusion and exclusion criteria and standardised definitions of success and failure. Main outcome measures: mean diurnal IOP (mdIOP, mean of 6 measurements), diurnal peak IOP, diurnal IOP fluctuations, glaucoma medical therapy, success rates, visual acuity, and severe adverse events. Both procedures are equally effective and safe in lowering mdIOP in patients with POAG. Because the micro shunt is less invasive with less follow‐up and interventions needed postoperatively, it might be recommended earlier in the treatment of glaucoma.
Like
Save
Share